Infectologia
Há necessidade urgente de um correlato de proteção para as vacinas contra o SARS-CoV-2 – “Estudos recentes sugerem que os anticorpos neutralizantes podem servir como um correlato de proteção para as vacinas contra o SARS-CoV-2 em humanos.”
12 Jul, 2021 | 11:31hA correlate of protection for SARS-CoV-2 vaccines is urgently needed – Nature Medicine
Relacionado: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
OMS afirma que os benefícios das vacinas de mRNA contra a COVID são superiores aos raros riscos cardíacos.
12 Jul, 2021 | 11:30hBenefits of mRNA COVID vaccines outweigh rare heart risks, says WHO – Reuters
Ver também: EU finds potential link between heart inflammation and mRNA COVID shots – Reuters E Heart inflammation link to Pfizer and Moderna jabs – BBC
Relatório oficial do American Thoracic Society Workshop | Entendendo o hospedeiro no tratamento da pneumonia.
12 Jul, 2021 | 11:26hEstudo randomizado | Outro estudo mostra a segurança do tratamento ambulatorial sem antibióticos na diverticulite aguda leve.
12 Jul, 2021 | 11:19hEfficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link para o resumo – $ para o texto completo)
Relacionado: State of the Art Review: Management of colonic diverticulitis E Treatment of Uncomplicated Acute Diverticulitis Without Antibiotics: A Systematic Review and Meta-analysis – Diseases of the Colon & Rectum E Antibiotics Do Not Reduce Length of Hospital Stay for Uncomplicated Diverticulitis in a Pragmatic Double-Blind Randomized Trial – Clinical Gastroenterology and Hepatology E Randomized Trial: Antibiotic Avoidance Associated with Similar Long-term Outcomes in Uncomplicated Diverticulitis
Comentário no Twitter
Another (final?) nail in the coffin for antibiotics in uncomplicated diverticulitis? DINAMO study from Spain – Outpatient treatment with antibiotics versus symptomatic Tx.
No difference in hospitalization rate or revisits to ER.https://t.co/wOc3tBGfxr @AnnalsofSurgery
— Ville Sallinen (@villesallinen) July 9, 2021
Estudo randomizado | CoronaVac mostrou eficácia de 83,5% na prevenção de infecção sintomática por SARS-CoV-2.
9 Jul, 2021 | 16:13hComentário convidado: CoronaVac: more data for regulators and policy makers
Comentário no Twitter
NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against symptomatic #COVID19. More research is needed to confirm efficacy in the long term, in a more diverse group, and against emerging #variants of concern.
🔗 https://t.co/TN5b6wwclc pic.twitter.com/4zOvJFIIOH
— The Lancet (@TheLancet) July 8, 2021
Ponto do vista | 7-1-7: um princípio de organização, meta e métrica de responsabilidade para tornar o mundo mais seguro em relação a pandemias.
9 Jul, 2021 | 16:12h
Comentário no Twitter
#COVID19 makes it possible and necessary to review lessons learnt and develop a framework to prepare for future epidemics, writes Thomas Frieden et al.
In this Viewpoint, they propose a 7-1-7 target for outbreak detection, notification, and response: https://t.co/TACjUplpmF pic.twitter.com/4uaxxgxJq2
— The Lancet (@TheLancet) July 7, 2021
Consenso | Orientação para líderes em cuidado de saúde durante o estágio de recuperação da pandemia de COVID-19.
9 Jul, 2021 | 16:11hComentário: Experts issue pandemic-recovery guidance for health leaders – CIDRAP
Comentário no Twitter
32 experts in healthcare, health leadership, and public health from 17 countries collaborated to create a novel evidence- and expertise-informed framework of leadership imperatives during the recovery stage of the #COVID19 pandemic https://t.co/3gDKZIERBv
— JAMA Network Open (@JAMANetworkOpen) July 8, 2021
Depois da pandemia: perspectivas sobre a trajetória futura da COVID-19.
9 Jul, 2021 | 16:10hAfter the pandemic: perspectives on the future trajectory of COVID-19 – Nature
CDC | Uso de vacina de mRNA contra COVID-19 após relatos de miocardite entre vacinados – “A continuação do uso das vacinas de mRNA contra a COVID-19 em todos os grupos etários recomendados vai prevenir a morbidade e a mortalidade por COVID-19 em números que excedem muito o número de casos esperados de miocardite.”
9 Jul, 2021 | 16:06h
Comentário no Twitter
In a new @CDCMMWR, the Advisory Committee on Immunization Practices recommends everyone 12 & older get a #COVID19 vaccine. The benefits of vaccination in preventing illness & death outweigh the rare risk of heart inflammation after vaccination. More: https://t.co/iPjbhU5jeV. pic.twitter.com/IggrZ4DX7L
— CDC (@CDCgov) July 6, 2021
Sensibilidade reduzida da variante Delta do SARS-CoV-2 a neutralização por anticorpos.
9 Jul, 2021 | 16:04hReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization – Nature
Comentários: Study highlights need for full Covid vaccination to protect against Delta variant – STAT E How does the Delta variant dodge the immune system? Scientists find clues. – The New York Times
Comentário no Twitter (fio – clique para saber mais)
Just published @Nature
Delta variant protection by mRNA and AZ vaccines requires 2-doses, little neutralizing antibody (nAb) with 1-dose, and insufficient nAb with prior covidhttps://t.co/TOgJdMe0g6 pic.twitter.com/KWLb9rBZ44— Eric Topol (@EricTopol) July 8, 2021